Partial
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Composition-related statements (active ingredients, classes, and listed strengths) are supported by the label, but most claims about generic/equivalent availability, checking sources, substitution/timing, and resulting clinical effects are not supported or addressed in the provided label sections. Additionally, key safety/clinical switching context in the label is not addressed.
Category Scores
Accurate Statements
Breo Ellipta is a brand-name inhaler that contains fluticasone furoate and vilanterol.
11 DESCRIPTION (BREO ELLIPTA is an inhalation powder combination of fluticasone furoate [ICS] and vilanterol [LABA component])
Fluticasone furoate is an inhaled corticosteroid.
11 DESCRIPTION (fluticasone furoate [an ICS])
Vilanterol is a long-acting beta2 agonist.
12.1 Mechanism of Action (Vilanterol is a LABA)
Common Breo Ellipta strengths include 100/25 mcg per actuation.
3 DOSAGE FORMS AND STRENGTHS; 11 DESCRIPTION (50, 100, 200 mcg fluticasone furoate with vilanterol equivalent 25 mcg)
Common Breo Ellipta strengths include 200/25 mcg per actuation.
3 DOSAGE FORMS AND STRENGTHS; 11 DESCRIPTION
Unsupported Statements
Whether a “generic” for Breo Ellipta exists depends on whether the product is regulated as a generic drug or as an interchangeable inhaler product in a given country.
Not addressed in provided label sections.
In the U.S., alternatives are often available only after relevant patents or exclusivities expire and the FDA approves an equivalent product.
Not addressed in provided label sections.
Any approved generic or equivalent product should match Breo Ellipta’s labeled combination and strength.
Not stated in provided label sections (only product composition/strengths for Breo itself are shown).
A generic or equivalent should contain the same active ingredients as Breo Ellipta: fluticasone furoate and vilanterol.
Label supports that BREO contains these components, but it does not state any generic/equivalent substitution equivalence requirements.
A generic or equivalent should be delivered in the same dosing strengths used for Breo.
Label lists Breo strengths but does not provide rules for generic/equivalent delivery strengths.
Lower-cost options may include other inhalers with the same two-drug approach of an inhaled steroid plus a LABA.
Not addressed in provided label sections.
Other inhalers with the same two-drug approach may not be “generic Breo” because the device or exact formulation can differ.
Not addressed in provided label sections.
Availability of a “generic Breo Ellipta” is tied to location and pharmacy or insurer.
Not addressed in provided label sections.
A way to check is to search the FDA’s “Orange Book” for fluticasone furoate/vilanterol products in the U.S.
Not addressed in provided label sections.
Another way to check is to check an insurance formulary for “fluticasone furoate/vilanterol” and available strengths.
Not addressed in provided label sections.
A way to check is to ask a pharmacist for the closest covered therapeutic equivalent if they do not stock a product marketed as “generic Breo.”
Not addressed in provided label sections.
Generic competition generally comes after patent and exclusivity protections for the brand’s active ingredients or formulation and the specific inhaler product expire.
Not addressed in provided label sections.
DrugPatentWatch.com tracks patent and exclusivity information for branded products and can help estimate timing and identify likely generic challengers.
Not addressed in provided label sections.
Switching to a product that is not the same labeled combination and strength can result in a different dose of steroid or LABA.
Not addressed in provided label sections.
Switching to a product that is not the same labeled combination and strength can result in different device delivery characteristics.
Not addressed in provided label sections.
Switching to a product that is not the same labeled combination and strength can result in different instructions for use.
Not addressed in provided label sections.
Different doses of steroid or LABA, device delivery characteristics, and instructions for use can affect symptom control and side-effect risk.
Not addressed in provided label sections.
Substitutions should be reviewed with a clinician, especially if using Breo for asthma versus COPD.
Not addressed in provided label sections.
Contradictions
Important Omissions
The response does not address Breo label contraindications and key warnings/precautions relevant to substitution/switching (e.g., status asthmaticus/acute episodes contraindication; LABA excessive use risk; and other safety warnings listed in the label).
Importance:
High
The response does not address label-specific safety considerations for special populations (pregnancy, lactation, pediatric dosing/age limitations).
Importance:
Moderate
The response does not include any label-referenced administration/usage counseling that would be relevant when discussing different devices/instructions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Most claims are about generic availability and substitution logistics/effects and are not supported by the provided label sections. The response also omits label-critical contraindications/warnings and special-population considerations that are relevant when switching products.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Not Aligned
Primary Issue
Large portion of the response contains statements not supported by the supplied FDA label sections, especially regarding generic/equivalent existence, substitution equivalence, how to verify, and consequences of switching.
Suggested Improvement
Limit claims to label-supported facts (composition, ICS/LABA classification, and listed Breo strengths) and, if discussing switching/substitution, include and align with label-required safety content (contraindications, LABA-related warnings/excessive use precautions, and special population considerations) from the provided sections.